Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Human papillomavirus HPV infection is very common and often causes warts, which can appear at any age. This trial is studying the effectiveness of two treatments, 2LVERU JUNIOR and 2LVERU, compared to a placebo in helping warts disappear. It is a randomized, placebo-controlled, double-blind study aiming to evaluate the disappearance of warts at 6 months after treatment. Participants will take one capsule daily, 15-30 minutes before breakfast on an empty stomach, following a sequence of capsules numbered 1 through 10, continuing this cycle for 6 months. The study includes two groups one receiving 2LVERU JUNIOR or 2LVERU and the other receiving a placebo. After the 6-month treatment phase, participants will be followed for an additional 3 months to monitor wart recurrence. During the study, participants will visit their doctor for assessments of wart disappearance at 4 and 6 months, pain evaluation, and safety monitoring through reports of adverse events. The main outcome is the complete disappearance of warts at 6 months, judged by normal skin color, texture, and touch at the wart site. The total study duration may last up to 45 months, including 36 months of patient enrollment and 9 months of follow-up.
Actively Recruiting
Herpes simplex virus HSV infection is very common and usually causes sores that can appear at any age. There is currently no antiviral treatment that completely cures or eradicates the virus. This clinical trial is designed to evaluate the effectiveness of 2LHERP4, an immune regulator used in treating herpetic infections, in reducing the recurrence of orofacial herpes infections in adults. Participants will be randomly assigned to receive either 2LHERP4 or a placebo for 6 months. The treatment involves taking one capsule daily before breakfast on an empty stomach, following a sequential order from capsule 1 to 10 and then repeating. After the treatment phase, there will be a 6-month follow-up period to assess the long-term effects of the treatment. During the study, participants will be monitored for the number and duration of herpes episodes, time to first recurrence, symptom severity including pain, use of rescue medication, quality of life, and safety. Data will be collected through patient diaries, questionnaires, and clinical assessments over a total duration of 12 months after treatment initiation to evaluate the efficacy and safety of 2LHERP4 compared to placebo.